Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Treasury Shares (2020 - 2024)

Historic Treasury Shares for Protalix BioTherapeutics (PLX) over the last 9 years, with Q4 2024 value amounting to $862816.0.

  • Protalix BioTherapeutics' Treasury Shares fell 2648.56% to $862816.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $862816.0, marking a year-over-year decrease of 2648.56%. This contributed to the annual value of $862816.0 for FY2024, which is 2648.56% down from last year.
  • Per Protalix BioTherapeutics' latest filing, its Treasury Shares stood at $862816.0 for Q4 2024, which was down 2648.56% from $1.2 million recorded in Q4 2023.
  • Over the past 5 years, Protalix BioTherapeutics' Treasury Shares peaked at $1.2 million during Q4 2023, and registered a low of $291474.0 during Q4 2022.
  • Moreover, its 5-year median value for Treasury Shares was $624580.0 (2020), whereas its average is $682113.4.
  • In the last 5 years, Protalix BioTherapeutics' Treasury Shares crashed by 3636.31% in 2022 and then skyrocketed by 30266.71% in 2023.
  • Quarter analysis of 5 years shows Protalix BioTherapeutics' Treasury Shares stood at $624580.0 in 2020, then dropped by 26.67% to $458027.0 in 2021, then crashed by 36.36% to $291474.0 in 2022, then surged by 302.67% to $1.2 million in 2023, then fell by 26.49% to $862816.0 in 2024.
  • Its Treasury Shares was $862816.0 in Q4 2024, compared to $1.2 million in Q4 2023 and $291474.0 in Q4 2022.